Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Adjuvant gefitinib improves outcomes in non-small cell lung cancer (NSCLC) patients compared to chemotherapy, but not in all cases. Here, the authors find genomic biomarkers of response to gefitinib in NSCLC patients from the ADJUVANT trial, and propose a score to stratify them by potential benefit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Si-Yang Liu, Hua Bao, Qun Wang, Wei-Min Mao, Yedan Chen, Xiaoling Tong, Song-Tao Xu, Lin Wu, Yu-Cheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Sheng-Xiang Ren, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Song Dong, Xu-Chao Zhang, Jian Su, Jin-Ji Yang, Xue-Ning Yang, Qing Zhou, Xue Wu, Yang Shao, Wen-Zhao Zhong, Yi-Long Wu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/c64a379b331b42709e78b568f7636af6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c64a379b331b42709e78b568f7636af6
record_format dspace
spelling oai:doaj.org-article:c64a379b331b42709e78b568f7636af62021-11-14T12:34:57ZGenomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes10.1038/s41467-021-26806-72041-1723https://doaj.org/article/c64a379b331b42709e78b568f7636af62021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26806-7https://doaj.org/toc/2041-1723Adjuvant gefitinib improves outcomes in non-small cell lung cancer (NSCLC) patients compared to chemotherapy, but not in all cases. Here, the authors find genomic biomarkers of response to gefitinib in NSCLC patients from the ADJUVANT trial, and propose a score to stratify them by potential benefit from the treatment.Si-Yang LiuHua BaoQun WangWei-Min MaoYedan ChenXiaoling TongSong-Tao XuLin WuYu-Cheng WeiYong-Yu LiuChun ChenYing ChengRong YinFan YangSheng-Xiang RenXiao-Fei LiJian LiCheng HuangZhi-Dong LiuShun XuKe-Neng ChenShi-Dong XuLun-Xu LiuPing YuBu-Hai WangHai-Tao MaHong-Hong YanSong DongXu-Chao ZhangJian SuJin-Ji YangXue-Ning YangQing ZhouXue WuYang ShaoWen-Zhao ZhongYi-Long WuNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Si-Yang Liu
Hua Bao
Qun Wang
Wei-Min Mao
Yedan Chen
Xiaoling Tong
Song-Tao Xu
Lin Wu
Yu-Cheng Wei
Yong-Yu Liu
Chun Chen
Ying Cheng
Rong Yin
Fan Yang
Sheng-Xiang Ren
Xiao-Fei Li
Jian Li
Cheng Huang
Zhi-Dong Liu
Shun Xu
Ke-Neng Chen
Shi-Dong Xu
Lun-Xu Liu
Ping Yu
Bu-Hai Wang
Hai-Tao Ma
Hong-Hong Yan
Song Dong
Xu-Chao Zhang
Jian Su
Jin-Ji Yang
Xue-Ning Yang
Qing Zhou
Xue Wu
Yang Shao
Wen-Zhao Zhong
Yi-Long Wu
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
description Adjuvant gefitinib improves outcomes in non-small cell lung cancer (NSCLC) patients compared to chemotherapy, but not in all cases. Here, the authors find genomic biomarkers of response to gefitinib in NSCLC patients from the ADJUVANT trial, and propose a score to stratify them by potential benefit from the treatment.
format article
author Si-Yang Liu
Hua Bao
Qun Wang
Wei-Min Mao
Yedan Chen
Xiaoling Tong
Song-Tao Xu
Lin Wu
Yu-Cheng Wei
Yong-Yu Liu
Chun Chen
Ying Cheng
Rong Yin
Fan Yang
Sheng-Xiang Ren
Xiao-Fei Li
Jian Li
Cheng Huang
Zhi-Dong Liu
Shun Xu
Ke-Neng Chen
Shi-Dong Xu
Lun-Xu Liu
Ping Yu
Bu-Hai Wang
Hai-Tao Ma
Hong-Hong Yan
Song Dong
Xu-Chao Zhang
Jian Su
Jin-Ji Yang
Xue-Ning Yang
Qing Zhou
Xue Wu
Yang Shao
Wen-Zhao Zhong
Yi-Long Wu
author_facet Si-Yang Liu
Hua Bao
Qun Wang
Wei-Min Mao
Yedan Chen
Xiaoling Tong
Song-Tao Xu
Lin Wu
Yu-Cheng Wei
Yong-Yu Liu
Chun Chen
Ying Cheng
Rong Yin
Fan Yang
Sheng-Xiang Ren
Xiao-Fei Li
Jian Li
Cheng Huang
Zhi-Dong Liu
Shun Xu
Ke-Neng Chen
Shi-Dong Xu
Lun-Xu Liu
Ping Yu
Bu-Hai Wang
Hai-Tao Ma
Hong-Hong Yan
Song Dong
Xu-Chao Zhang
Jian Su
Jin-Ji Yang
Xue-Ning Yang
Qing Zhou
Xue Wu
Yang Shao
Wen-Zhao Zhong
Yi-Long Wu
author_sort Si-Yang Liu
title Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
title_short Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
title_full Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
title_fullStr Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
title_full_unstemmed Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
title_sort genomic signatures define three subtypes of egfr-mutant stage ii–iii non-small-cell lung cancer with distinct adjuvant therapy outcomes
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/c64a379b331b42709e78b568f7636af6
work_keys_str_mv AT siyangliu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT huabao genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT qunwang genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT weiminmao genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT yedanchen genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT xiaolingtong genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT songtaoxu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT linwu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT yuchengwei genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT yongyuliu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT chunchen genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT yingcheng genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT rongyin genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT fanyang genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT shengxiangren genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT xiaofeili genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT jianli genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT chenghuang genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT zhidongliu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT shunxu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT kenengchen genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT shidongxu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT lunxuliu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT pingyu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT buhaiwang genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT haitaoma genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT honghongyan genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT songdong genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT xuchaozhang genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT jiansu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT jinjiyang genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT xueningyang genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT qingzhou genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT xuewu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT yangshao genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT wenzhaozhong genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
AT yilongwu genomicsignaturesdefinethreesubtypesofegfrmutantstageiiiiinonsmallcelllungcancerwithdistinctadjuvanttherapyoutcomes
_version_ 1718429129900032000

Ejemplares similares